Plain-English translation of NCT07672860 on ClinicalTrials.gov ↗ ·
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether ursodeoxycholic acid (UDCA)—a naturally occurring bile acid with a long safety record—can protect your kidneys during partial nephrectomy, a surgery to remove a small kidney tumor. During this operation, doctors temporarily clamp the renal artery to control bleeding, which briefly cuts off blood flow to the kidney and can cause injury when blood flow is restored. This medication is being tested to see if it can reduce that injury and help preserve kidney function after surgery.
When the blood supply to your kidney is temporarily stopped during cancer surgery and then restored, it can trigger inflammation and damage that increases the risk of acute kidney injury and long-term loss of kidney function. Currently, there is no proven medication doctors can give during this surgery to prevent that damage, so this trial is investigating whether this medication might fill that gap.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive either the medication or a placebo (dummy pill) three times daily starting before your surgery and continuing for a period after. The first six patients will receive the actual medication as a safety check before the full randomized study begins. You will have your kidney function monitored through blood and urine tests, and doctors will track how well your kidneys recover after surgery. The study team will measure kidney injury markers and liver function to make sure the treatment is safe and effective.
AI-generated summary from trial data · Jul 6, 2026 · Not medical advice
China